Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1781-1790 Newer>

The Motley Fool February 17, 2005 Karl Thiel	Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market.
The Motley Fool February 17, 2005 Stephen D. Simpson	Is Medtronic's Heartbeat Slowing? Will gradually decelerating growth lead to a multiple contraction on the medical device maker's stock?
The Motley Fool February 17, 2005 Rich Smith	LabCorp Tests Positive The results show strong bottom-line growth for the health-care test provider. Compared to the pricier Quest, it's at least a relative bargain price at which investors can own an interest in this essential piece of the health-care market.
The Motley Fool February 17, 2005 Stephen D. Simpson	Caremark Hits the Mark Again With expectations of higher than 25% growth in 2005, the pharmacy benefits manager looks like it will continue to take care of its investors.
Reactive Reports Issue 43 David Bradley	Polymer Technology Saves Face PolyHap readily bonds with bone with no adverse side effects. The material might ultimately replace titanium in prosthetics and bone repair surgery. The material is currently undergoing clinical trials in Moscow.
The Motley Fool February 16, 2005 Tom Taulli	Lifeline Gets Better With Time As baby boomers age, they'll need more health-care services. Lifeline Systems is counting on it. But don't jump aboard without making a peek inside the valuation first.
The Motley Fool February 15, 2005 Charly Travers	Searching for Cheap Biotechs Can a stock screen turn up a winner? Remember, the screen just gives a short list of potential ideas and some guidance as to where a good place to look may be. But it is not a replacement for doing research on a company's drug programs and management team.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool February 15, 2005 Stephen D. Simpson	Psychiatric Solutions Healthy Provider of in-patient mental health services continues to grow rapidly, but debt and dilution are reason for pause.
The Motley Fool February 15, 2005 Stephen D. Simpson	Axcan's Got Guts While growth for this Canadian drug company is a bit sluggish, ITAX could be a major winner. Investors looking at Axcan shares should treat this stock like a hybrid biotech stock.
<Older 1781-1790 Newer> Return to current articles.